Beam Therapeutics Inc logo

BEAM

Beam Therapeutics Inc

$25.23

Earnings Summary

Revenue
$20.12Mn
Net Profits
$-82.78Mn
Net Profit Margins
-411.49%

Highlights

Revenue:

Beam Therapeutics Inc’s revenue jumped 20.8% since last year same period to $20.12Mn in the Q2 2023. On a quarterly growth basis, Beam Therapeutics Inc has generated -16.9% fall in its revenue since last 3-months.

Net Profits:

Beam Therapeutics Inc’s net profit fell -15.05% since last year same period to $-82.78Mn in the Q2 2023. On a quarterly growth basis, Beam Therapeutics Inc has generated 14.19% jump in its net profits since last 3-months.

Net Profit Margins:

Beam Therapeutics Inc’s net profit margin jumped 4.76% since last year same period to -411.49% in the Q2 2023. On a quarterly growth basis, Beam Therapeutics Inc has generated -3.27% fall in its net profit margins since last 3-months.

Earnings per share (EPS) Estimates

Earnings per share (EPS) estimates of the Beam Therapeutics Inc post its latest quarter earnings

EPS Estimate Current Quarter
-1.34
EPS Estimate Current Year
-1.34

Highlights

EPS Estimate Current Quarter:

Beam Therapeutics Inc’s earning per share (EPS) estimates for the current quarter stand at -1.34 - a -2.29% fall from last quarter’s estimates.

EPS Estimate Current Year:

Beam Therapeutics Inc’s earning per share (EPS) estimates for the current year stand at -1.34.

Key Ratios

Key ratios of the Beam Therapeutics Inc post its Q1 2023 earnings

Return on Assets (ROA)
-0.17
Return on Equity (ROE)
-0.37

Highlights

Return on Assets (ROA):

Return on assets (ROA) indicates the profitability of the company in relation to its total assets. This ratio tells the financial health of the company. The higher the ROA, the better the company’s financial health. If any company has a ROA in the range of 5% to 20% - it is generally considered good. ROA above 20% is generally considered excellent. Beam Therapeutics Inc’s return on assets (ROA) stands at -0.17.

Earning Per Share (EPS):

The Return On Equity ratio indicates a company’s ability to turn equity capital received from shareholders into profits. ROE highlights the efficiency of equity capital in running the business. Generally, a return on equity in double digits is considered good. Beam Therapeutics Inc’s return on equity (ROE) stands at -0.37.

Earnings Calendar

Earnings DateEstimated EPSReported EPSSurprise %
2022-08-09
-1.08
-1.02
5.56%
2022-05-09
-1.32
-1.01
23.48%
2022-11-07
-1.31
-1.56
-19.08%